Patents by Inventor Young Kee Shin

Young Kee Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210009720
    Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same.
    Type: Application
    Filed: September 16, 2020
    Publication date: January 14, 2021
    Inventors: Young Kee SHIN, Young Deug KIM, Jun Young CHOI, Tae Eun KIM, Young Jin LEE, Ju Ho LEE, Yeong Mun KIM
  • Patent number: 10847793
    Abstract: A negative active material for a rechargeable lithium battery includes a lithium titanate compound represented by Chemical Formula 1, where R, a Raman spectrum intensity ratio (I(F2u)/I(F2g)) of an F2u peak in a range of about 200 cm?1 to about 300 cm?1 relative to an F2g peak in a range of about 400 cm?1 to about 550 cm?1 is greater than or equal to about 0.7. Li4+xTi5?yMzO12?n??Chemical Formula 1 In Chemical Formula 1, ?0.2?x?0.2, ?0.3?y?0.3, 0?z?0.3, ?0.3?n?0.3, and M is selected from Mg, Al, Ca, Sr, Cr, V, Fe, Co, Ni, Zr, Zn, Si, Y, Nb, Ga, Sn, Mo, W, Ba, La, Ce, Ag, Ta, Hf, Ru, Bi, Sb, As, and a combination thereof.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: November 24, 2020
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Soojeong Lee, Young-Kee Kim, Dong-Hyun Shin, Sun-Il Park, Sujin Um
  • Patent number: 10806799
    Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: October 20, 2020
    Assignee: GENOPHARM INC.
    Inventors: Young Kee Shin, Young Deug Kim, Jun Young Choi, Tae Eun Kim, Young Jin Lee, Ju Ho Lee, Yeong Mun Kim
  • Patent number: 10718030
    Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy. Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient, and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 21, 2020
    Assignee: GENCURIX INC.
    Inventors: Sang Rae Cho, Young Ho Moon, Jin Il Han, Young Kee Shin
  • Patent number: 10655187
    Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: May 19, 2020
    Assignee: GENCURIX INC.
    Inventors: Young Kee Shin, Young-Deug Kim, En Sel Oh, Jun Young Choi, Sang Rea Cho
  • Publication number: 20200102595
    Abstract: The present invention relates to a method for determining the DNA quality of a biological sample and, more specifically, to a method for determining the DNA quality of a biological sample by performing a quantitative polymerase chain reaction (PCR) using primers capable of amplifying a target gene, a method for preparing the primers used in the method, and a method for standardizing the amount of detected target gene mutation by using the determined DNA quality. The method of the present invention enables objective evaluation of the NDA quality of a biological sample used in gene analysis and the presentation of objective results on the expression ratio of a gene mutation, thereby providing reliable information in the fields of clinical research and companion diagnosis.
    Type: Application
    Filed: April 4, 2018
    Publication date: April 2, 2020
    Inventors: Young Kee SHIN, Jin Ju KIM, Sung Su KIM, Hyun Jeung CHOI, Young Ho MOON, Myung Sun KIM
  • Publication number: 20200071768
    Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 5, 2020
    Inventors: Sang Rae CHO, Young Ho MOON, Jin Il HAN, Young Kee SHIN
  • Patent number: 10576158
    Abstract: An immune conjugate according to the present invention provides a pharmaceutical composition, which can be used in the target-oriented drug treatment by conjugating a dendron allowing a plurality of drugs to be bound to a surface thereof and a target-directed antibody, and especially, can deliver high concentrations of drugs in a tumor-specific manner to exhibit a strong anticancer effect by conjugating a hydrophilic dendron, to which a plurality of anticancer drugs are bound, to an antibody.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 3, 2020
    Assignee: ABION INC.
    Inventors: Young Deug Kim, Eun Ji Park, Yejin Kim, Young Kee Shin, Jun Young Choi
  • Publication number: 20200009185
    Abstract: The present invention relates to a method for maintaining the increased intracellular p53 level, induced by a platinum-based anticancer drug, and an application thereof and, more specifically, to a method for maintaining the increased intracellular p53 level in cells by administering a platinum-based anticancer drug and siRNA to ubiquitin ligase for p53 to a subject in need thereof in combination and sequentially, and a composition for promoting cancer cell apoptosis using the same. According to the method of the present invention, the increased intracellular p53 expression level can be maintained for a long period of time in spite of the treatment with a low-concentration platinum-based anticancer drug, thereby effectively inducing the apoptosis of cancer cells and minimizing the drug side effect caused by the administration of the platinum-based anticancer drug, and thus the present invention can be favorably used in the prevention of cancer or the development of cancer medicines.
    Type: Application
    Filed: July 24, 2019
    Publication date: January 9, 2020
    Inventors: Young Kee Shin, Young Deug Kim, Hun Soon Jung, Deuk Ae Kim, Nirmal Rajasekaran
  • Publication number: 20190352703
    Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.
    Type: Application
    Filed: May 25, 2017
    Publication date: November 21, 2019
    Inventors: Young Kee SHIN, Bohyun BYUN, Hyunjeung CHOI, Joon Seok CHOI, Young Ho MOON, Jong Heun LEE, Sang Rea CHO, Jee Eun KIM, Myungsun KIM
  • Patent number: 10464038
    Abstract: A mixer and a reactor including the same are provided. According to one aspect of the present invention, the mixer includes a first piping part into which a first fluid flows, an elbow piping part having an inlet connected to the first piping part and an outlet provided at a location rotated by a predetermined angle from the inlet in a flow direction of the first fluid to have a curved flow path, and a second piping part connected to the elbow piping part to have a central axis perpendicular to a central axis of the first piping part so that a second fluid flows in a tangential direction of the elbow piping part when the second fluid flows into the elbow piping part.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: November 5, 2019
    Assignee: LG Chem, Ltd.
    Inventors: Jung Kee Jang, Hyun Jin Shin, Young Soo Song
  • Patent number: 10428386
    Abstract: The present invention relates to a method for selecting a gene intended to predict the prognosis for a cancer, to the selected gene for predicting the prognosis of cancer and to a kit for predicting and a method for predicting metastasis in breast-cancer patients by using the same. In the present invention, a straight forward method is used to achieve high-reliability prediction of the patient's prognosis by analyzing for the genetic characteristics of early stage breast cancer, and thus the present invention can be used to advantage in prognosis diagnosis which can reduce unnecessary anticancer therapy.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 1, 2019
    Assignee: GENCURIX INC.
    Inventors: Young Kee Shin, Young-Deug Kim, En Sel Oh, Si Eun Kim
  • Patent number: 10404828
    Abstract: Provided are a streaming apparatus, a streaming method, and a streaming service system using the streaming apparatus, wherein the streaming apparatus includes: a scheduler configured to generate a modified metafile by modifying a reproduction list file of a metafile; and a server socket configured to transmit the modified metafile when a metafile transmit request is received from a player by operating as a server with respect to the player. Accordingly, delay times of players are substantially the same.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: September 3, 2019
    Assignee: Naver Corporation
    Inventors: Sung Tak Cho, Sung Ho Kim, Joon Kee Chang, Min Hee Choi, Ki Su Park, Kyoung Yun Kang, Young Min Kim, Dong Ock Kim, Eun Sun Shin
  • Publication number: 20190248878
    Abstract: The present invention provides: an antibody which specifically bonds to human NINJ-1; and a fragment thereof. The antibody or the fragment thereof according to the present invention has very high bonding affinity and bonding specificity with respect to a human NINJ-1 or a homogeneous binding site of the protein, and does not exhibit cross-reactivity with NINJ-1 proteins that are derived from other organisms and have high protein similarity. Accordingly, the present invention provides significant advantages with respect to accuracy and sensitivity and the like, not only in diagnosing disease related to NINJ-1 proteins but also in inhibiting pathological conditions involving NINJ-1 proteins. In particular, the antibody provided according to the present invention has a remarkable effect of inhibiting attachment between immunocytes and human cerebral endothelial cells, and thus has an effect of treating multiple sclerosis.
    Type: Application
    Filed: August 28, 2017
    Publication date: August 15, 2019
    Inventors: Young Kee SHIN, Seahyung LEE, Kyoung SONG, Ji Hye LEE
  • Publication number: 20190161808
    Abstract: The present invention relates to a method for predicting the prognosis of breast cancer patients by using gene deletions and, more particularly, to: a method for detecting a marker for the prognosis of triple negative breast cancer patients in order to provide information necessary for the breast cancer prognosis diagnosis, comprising the steps of obtaining a sample of a subject, extracting genomic DNA from the sample, examining deletions of genes in the extracted genomic DNA, and determining that a subject, in which gene deletions in genomic DNA are confirmed, has a poor prognosis for breast cancer; and a composition for predicting the prognosis of breast cancer patients, containing a preparation enabling the examination of gene deletions and a kit comprising the same as an active ingredient.
    Type: Application
    Filed: May 12, 2017
    Publication date: May 30, 2019
    Inventors: Young Kee SHIN, Hae Min JEONG, Ryongnam KIM
  • Patent number: 10304561
    Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 28, 2019
    Assignees: ABION, Inc., GENCURIX INC.
    Inventors: Young Kee Shin, Mi J. Kwon, En Sel Oh, Yong H. In, Sang S. Koh
  • Patent number: 10221418
    Abstract: The present invention relates to a composition for preventing or treating diseases associated with human papillomavirus (HPV), and more specifically, cancer associated with HPV, and even more specifically, cervical cancer. The nucleotide sequence of the present invention, the sequence in which the base thereof is modified, and a specific combination thereof can be useful in a composition for effectively treating diseases associated with HPV infection by greatly inhibiting the expression of the E6/E7 gene of HPV type 16 or 18.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: March 5, 2019
    Assignee: EnhancedBio Inc.
    Inventors: Young Kee Shin, Young Deug Kim, Hun Soon Jung, Deuk Ae Kim
  • Publication number: 20190040473
    Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.
    Type: Application
    Filed: October 9, 2018
    Publication date: February 7, 2019
    Inventors: Young Kee SHIN, Young-Deug KIM, En Sel OH, Jun Young CHOI, Sang Rea CHO
  • Publication number: 20190017121
    Abstract: The present invention relates to a method for selecting a gene intended to predict the prognosis for a cancer, to the selected gene for predicting the prognosis of cancer and to a kit for predicting and a method for predicting metastasis in breast-cancer patients by using the same. In the present invention, a straight forward method is used to achieve high-reliability prediction of the patient's prognosis by analysing for the genetic characteristics of early stage breast cancer, and thus the present invention can be used to advantage in prognosis diagnosis which can reduce unnecessary anticancer therapy.
    Type: Application
    Filed: October 4, 2016
    Publication date: January 17, 2019
    Inventors: YOUNG KEE SHIN, YOUNG-DEUG KIM, EN SEL OH, SI EUN KIM
  • Publication number: 20190012429
    Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.
    Type: Application
    Filed: September 12, 2018
    Publication date: January 10, 2019
    Inventors: Young Kee Shin, Mi Jeong Kwon, En Sel Oh, Yong Ho In, Sang Seok Koh